Journals / Çocuk Dergisi / 2007 / Cilt: 7 - Sayı: 2

Congenital Hepatitis C Infection

Konjenital Hepatit C İnfeksiyonu

Pages
89–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

More effective and less toxic therapies for young patients with HCV are needed, as are methods to interrupt perinatal transmission of HCV.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Since the program of the hepatitis B virus vaccination started, hepatitis C virus (HCV) has become the most significant cause of chronic liver disease of infectious etiology in pediatric age.
📊
Key Findings & Data:After the introduction of hepatitis C virus screening of blood units, vertical transmission now seems to be the most common route of hepatitis C virus infection in children.
💡
Conclusion & Impact:More effective and less toxic therapies for young patients with HCV are needed, as are methods to interrupt perinatal transmission of HCV.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Viroloji · Terapötikler · Birincil önleme

Abstract

Since the program of the hepatitis B virus vaccination started, hepatitis C virus (HCV) has become the most significant cause of chronic liver disease of infectious etiology in pediatric age. After the introduction of hepatitis C virus screening of blood units, vertical transmission now seems to be the most common route of hepatitis C virus infection in children. Both viral and host related factors are of importance as risk factors in vertical HCV transmission. Although hepatitis C virus associated liver disease is usually mild throughout infancy and childhood, progression to chronicity occurs in the majority of perinatally infected children. Treatment of HCV infected children has not been studied extensively. More effective and less toxic therapies for young patients with HCV are needed, as are methods to interrupt perinatal transmission of HCV.

Özet

Hepatit B’ye karşı aşılama programlarının başlanmasından sonra Hepatit C (HCV) çocukluk yaş grubu içinde infeksiyon kaynaklı kronik karaciğer hastalığına neden olan başlıca etken olmuştur. HCV açısından kan ürünlerinin rutin taranmaya başlanması ile çocukların bu virus ile infekte olmasına neden olan en sık bulaşma yolunu anneden çocuğa vertikal geçiş oluşturmaya başlamıştır. Anneden çocuğa virus geçişini etkileyen en önemli risk faktörlerini konakçı ve virusun kendisi ile ilgili faktörler oluşturmaktadır. HCV’ye bağlı karaciğer hastalığı yenidoğan dönemi ve çocukluk çağında orta derecede bir hastalık olarak karşımıza çıkmasına rağmen, bu çocukların çoğunda ileriki dönemlerde kronik karaciğer hastalığı gelişebilmektedir. HCV ile enfekte çocukların tedavisi konusunda geniş kapsamlı araştırmalar mevcut değildir. HCV’nin perinatal geçişini engelleyebilecek yeni metodlara ve bu çocukların tedavisinde kullanılabilecek daha etkili ve daha az toksik ilaç tedavilerine gereksinim vardır.

🔖

Cite This Article

DALGIÇ, N. (2007). Congenital Hepatitis C Infection. Çocuk Dergisi, Cilt: 7 - Sayı: 2, 89–93. https://ajindex.com/articles/156934

References (15)

  1. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39:5-19
  2. Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16:296- 305
  3. Bradley JS. Hepatitis. In: Remington SS, Klein JO, Wilson CB, Baker CJ, eds. Infectious Diseases of the Fetus and Newborn Infant, 6th ed. Philadelphia, PA, IL: Elsevier Saunders, 2006: 823-43
  4. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30:595-601.5. Darling JM, Wright TL. Immune responses in hepatitis C: is virus or host the problem? Curr Opin Infect Dis 2004; 17:193-8
  5. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127:924-36
  6. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645-55
  7. Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol 2003; 24:456-64
  8. Chang MH. Mother-to-infant transmission of hepatitis C virus. Clin Invest Med 1996; 19:368-72
  9. England K, Pembrey L, Tovo PA, Newell ML. Growth in the first 5 years of life is unaffected in children with perinatally- acquired hepatitis C infection. J Pediatr 2005; 147:227- 32
  10. Pembreya L, Newella ML, Tovob PA. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol 2005; 43:515-25
  11. Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol 2004; 554:211-6
  12. Ruiz-Extremera A, Salmeron J, Torres C, et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000; 19:511-6
  13. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317:437-41
  14. Conte D, Colucci A, Minola E, Fraquelli M, Prati D. Clinical course of pregnant women with chronic hepatitis C virus infection and risk of mother-to-child hepatitis C virus transmission. Dig Liver Dis 2001; 33:366-71
  15. Ferrero S,